MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its

MONTREAL and CHARLOTTE, N.C., Sept. 8, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive

MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30,

MONTREAL and CHARLOTTE, N.C., Aug. 6, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive

- Recently completed NODE-301 and ongoing NODE-301B studies can be used as two efficacy studies supporting a future NDA submission (target p-values of

MONTREAL and CHARLOTTE, N.C. , July 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a securities purchase agreement

MONTREAL and CHARLOTTE, N.C. , May 27, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto , President and Chief Executive

MONTREAL and CHARLOTTE, N.C. , May 14, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2020

–  Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) – –  Etripamil showed rapid conversion of SVT to SR during the first 45 minutes (p=0.02), consistent with its known pharmacology – –  Study demonstrated a positive safety

– Topline data from Phase 3 NODE-301 trial of etripamil in patients with PSVT expected this month –   MONTREAL and CHARLOTTE, N.C. , March 6, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of